Extended dosing intervals of ixekizumab for psoriasis: A single-center, uncontrolled, prospective study

Authors :: Xue-Yan Chen
Bing-Xi Yan
Jia-Qi Chen
Li-Ran Ye
Xiao-Yong Man
Si-Qi Chen
Source :: Journal of the American Academy of Dermatology. 86:1348-1350
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Subjects :: medicine.medical_specialty
business.industry
MEDLINE
Dermatology
Antibodies, Monoclonal, Humanized
medicine.disease
Single Center
Severity of Illness Index
Ixekizumab
Treatment Outcome
Psoriasis
Internal medicine
medicine
Humans
Dermatologic Agents
Prospective Studies
Dosing
business
Prospective cohort study

Tools